These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
532 related articles for article (PubMed ID: 10197796)
1. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg). Kröger N; Zeller W; Hassan HT; Krüger W; Gutensohn K; Löliger C; Zander AR Bone Marrow Transplant; 1999 Jan; 23(2):125-9. PubMed ID: 10197796 [TBL] [Abstract][Full Text] [Related]
2. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Weaver CH; Schulman KA; Buckner CD Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117 [TBL] [Abstract][Full Text] [Related]
3. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF. Gómez-Espuch J; Moraleda JM; Ortuño F; Lozano ML; Ayala F; Vallejo C; de Arriba F; Vicente V Bone Marrow Transplant; 2000 Feb; 25(3):231-5. PubMed ID: 10673692 [TBL] [Abstract][Full Text] [Related]
4. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients. Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956 [TBL] [Abstract][Full Text] [Related]
5. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection. Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627 [TBL] [Abstract][Full Text] [Related]
6. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Alegre A; Tomás JF; Martínez-Chamorro C; Gil-Fernández JJ; Fernández-Villalta MJ; Arranz R; Díaz MA; Granda A; Bernardo MR; Escudero A; López-Lorenzo JL; Fernández-Rañada JM Bone Marrow Transplant; 1997 Aug; 20(3):211-7. PubMed ID: 9257889 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors. Martínez C; Urbano-Ispizua A; Marín P; Merino A; Rovira M; Carreras E; Montserrat E Bone Marrow Transplant; 1999 Dec; 24(12):1273-8. PubMed ID: 10627634 [TBL] [Abstract][Full Text] [Related]
8. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983 [TBL] [Abstract][Full Text] [Related]
9. A randomised study of 10 microg/kg/day (single dose) vs 2 x 5 microg/kg/day (split dose) G-CSF as stem cell mobilisation regimen in high-risk breast cancer patients. Carrión R; Serrano D; Gómez-Pineda A; Díez-Martín JL Bone Marrow Transplant; 2003 Sep; 32(6):563-7. PubMed ID: 12953127 [TBL] [Abstract][Full Text] [Related]
10. Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC). Benet I; Prosper BF; Marugan I; Lluch A; Arbona C; Castillo I; Solano C; Garcia-Conde J Bone Marrow Transplant; 1999 Jun; 23(11):1101-7. PubMed ID: 10382948 [TBL] [Abstract][Full Text] [Related]
11. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Kröger N; Renges H; Krüger W; Gutensohn K; Löliger C; Carrero I; Cortes L; Zander AR Br J Haematol; 2000 Dec; 111(3):761-5. PubMed ID: 11122135 [TBL] [Abstract][Full Text] [Related]
12. Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer. Prince HM; Gardyn J; Millward MJ; Rischin D; Francis P; Gates P; Chapple P; Quinn M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P; Brettell M; Toner GC Bone Marrow Transplant; 1999 Mar; 23(5):427-35. PubMed ID: 10100555 [TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
14. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688 [TBL] [Abstract][Full Text] [Related]
15. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF. Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898 [TBL] [Abstract][Full Text] [Related]
16. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature. Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563 [TBL] [Abstract][Full Text] [Related]
17. [CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation]. Sawada H; Wake A; Yamasaki Y; Izumi Y Rinsho Ketsueki; 2000 Jun; 41(6):500-6. PubMed ID: 10921350 [TBL] [Abstract][Full Text] [Related]
18. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Stewart DA; Guo D; Morris D; Poon MC; Ruether BA; Jones AR; Klassen J; Auer I; Luider J; Chaudhry A; Brown C; Russell JA Bone Marrow Transplant; 1999 Jan; 23(2):111-7. PubMed ID: 10197794 [TBL] [Abstract][Full Text] [Related]
19. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. Sautois B; Fraipont V; Baudoux E; Fassotte MF; Hermanne JP; Jérusalem G; Bours V; Bosquée L; Schaaf-Lafontaine N; Paulus JM; Sondag D; Fillet G; Beguin Y Haematologica; 1999 Apr; 84(4):342-9. PubMed ID: 10190949 [TBL] [Abstract][Full Text] [Related]
20. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF. Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]